Patents by Inventor Bruce McManus
Bruce McManus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951258Abstract: A patient interface includes a plenum chamber pressurisable to a therapeutic pressure, and a seal-forming structure constructed and arranged to seal with a region of a patient's face surrounding an entrance to a patient's airways. The seal-forming structure is constructed and arranged to maintain the therapeutic pressure in the plenum chamber throughout a patient's respiratory cycle in use. The patient interface also includes a positioning and stabilizing structure configured to hold the seal-forming structure in a therapeutically effective position on a patients head. The positioning and stabilizing structure includes a rear strap arranged to contact an occiput of the patient's head. The rear strap is constructed from a first material is arranged to contact a temporal region of the patient's head, and a second material arranged to contact the occiput of the patients head. The second material is silicone.Type: GrantFiled: March 19, 2021Date of Patent: April 9, 2024Assignee: ResMed Pty LtdInventors: Memduh Guney, Stewart Joseph Wagner, Jeremy McManus, Daniel Marc Weiss, Michael Kenneth Truscott, Nwe Oo Tha, Bruce Richard Davies
-
Patent number: 10989716Abstract: The present disclosure relates to methods of diagnosing acute rejection of a cardiac allograft in a subject using genomic expression profiling, proteomic expression profiling, or both on panels of nucleic acid markers and proteomic markers.Type: GrantFiled: April 28, 2016Date of Patent: April 27, 2021Assignee: The University of British ColumbiaInventors: Bruce McManus, Raymond Ng, Scott Tebbutt, Janet Wilson-McManus, Zsuzsanna Hollander, Karen Lam, Virginia Chen, Darlene Dai, Casey Shannon, Andrew Ignaszewski, Robert Balshaw, Robert McMaster, Paul Keown
-
Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of COPD
Patent number: 10942188Abstract: Described are compositions and methods for diagnosing acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Multiple reaction monitoring mass spectrometry (MRM-MS) was used to quantify the amount of protein biomarkers in plasma samples from human subjects. The amount of the biomarkers in the sample can distinguish AECOPD from a stable or convalescent state of COPD, or from a subject without COPD.Type: GrantFiled: May 17, 2016Date of Patent: March 9, 2021Assignee: The University of British ColumbiaInventors: Don D. Sin, Raymond T. Ng, Bruce McManus, Zsuzsanna Hollander, Virginia Chen -
METHODS AND SYSTEMS OF DETECTING PLASMA PROTEIN BIOMARKERS FOR DIAGNOSING ACUTE EXACERBATION OF COPD
Publication number: 20190383830Abstract: Described are compositions and methods for diagnosing acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Multiple reaction monitoring mass spectrometry (MRM-MS) was used to quantify the amount of protein biomarkers in plasma samples from human subjects. The amount of the biomarkers in the sample can distinguish AECOPD from a stable or convalescent state of COPD, or from a subject without COPD.Type: ApplicationFiled: May 17, 2016Publication date: December 19, 2019Inventors: Don D. Sin, Raymond T. Ng, Bruce McManus, Zsuzsanna Hollander, Virginia Chen -
Publication number: 20180164326Abstract: The present disclosure relates to methods of diagnosing acute rejection of a cardiac allograft in a subject using genomic expression profiling, proteomic expression profiling, or both on panels of nucleic acid markers and proteomic markers.Type: ApplicationFiled: April 28, 2016Publication date: June 14, 2018Applicant: The University of British ColumbiaInventors: Bruce McManus, Raymond Ng, Scott Tebbutt, Janet Wilson-McManus, Zsuzsanna Hollander, Karen Lam, Virginia Chen, Darlene Dai, Casey Shannon, Andrew Ignaszewski, Robert Balshaw, Robert McMaster, Paul Keown
-
Patent number: 9176138Abstract: A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.Type: GrantFiled: April 25, 2014Date of Patent: November 3, 2015Assignee: The University of British ColumbiaInventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus
-
Patent number: 9060960Abstract: A method of medical treatment or prevention of a vasculopathy, comprising administering a therapeutically effective amount of a granzyme B inhibitor to a subject in need thereof is provided. In other aspects uses of Granzyme B inhibitors for treatment or for preparation of medicaments for treatment of a vasculopathy are provided.Type: GrantFiled: October 1, 2008Date of Patent: June 23, 2015Assignee: The University of British ColumbiaInventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus
-
Publication number: 20150133326Abstract: Disclosed herein is a method for determining recovered heart function in a subject based in the biomarker ceruloplasmin in patient samples. Also disclosed are computer systems, kits and software.Type: ApplicationFiled: April 18, 2013Publication date: May 14, 2015Inventors: Bruce McManus, Zsuzsanna Hollander, Andrew Ignaszewski, George Schreiner, Janet E. Wilson-McManus, Raymond T. Ng, Robert Balshaw, Paul Keown, Robert McMaster, Scott J. Tebbutt
-
Publication number: 20140255953Abstract: A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.Type: ApplicationFiled: April 25, 2014Publication date: September 11, 2014Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus
-
Patent number: 8715948Abstract: A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.Type: GrantFiled: April 22, 2013Date of Patent: May 6, 2014Assignee: The University of British ColumbiaInventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Bolvin, Bruce McManus
-
Publication number: 20130323749Abstract: A method for identifying a subject being at risk for or having a chronic Inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.Type: ApplicationFiled: April 22, 2013Publication date: December 5, 2013Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus
-
Patent number: 8426149Abstract: A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.Type: GrantFiled: October 1, 2008Date of Patent: April 23, 2013Assignee: The University of British ColumbiaInventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus
-
Publication number: 20110229546Abstract: A method of medical treatment or prevention of a vasculopathy, comprising administering a therapeutically effective amount of a granzyme B inhibitor to a subject in need thereof is provided. In other aspects uses of Granzyme B inhibitors for treatment or for preparation of medicaments for treatment of a vasculopathy are provided.Type: ApplicationFiled: October 1, 2008Publication date: September 22, 2011Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus
-
Publication number: 20110189680Abstract: A method of determining the acute allograft rejection status of a subject, the method comprising the steps of: determining the nucleic acid expression profile of one or more than one nucleic acid markers, or one or more than one proteomic markers in a biological sample from the subject; comparing the expression profile of the one or more than one nucleic acid markers to a control profile; and determining whether the expression level of the one or more than one nucleic acid markers is increased relative to the control profile, wherein the increase of the one or more than one nucleic acid markers is indicative of the acute rejection status of the subject.Type: ApplicationFiled: May 29, 2009Publication date: August 4, 2011Applicant: The University of British ColumbiaInventors: Paul Keown, Andreas Scherer, Oliver Gunther, Robert Balshaw, Raymond Ng, Alice Mui, Robert McMaster, Bruce McManus, Gabriela Cohen Freue, Anna Meredith
-
Publication number: 20110190151Abstract: The present invention relates to methods of diagnosing chronic rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, or a combination of genomic and proteomic expression profiling.Type: ApplicationFiled: April 9, 2009Publication date: August 4, 2011Inventors: Bruce McManus, Zsuzsanna Hollander, David Lin, Robert Balshaw, Robert McMaster, Paul Keown, Gabriela Cohen Freue, Janet Wilson-McManus, Raymond Ng
-
Publication number: 20110171645Abstract: The present invention relates to methods of diagnosing acute rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, metabolite profiling, or alloreactive T-cell genomic expression profiling,Type: ApplicationFiled: April 9, 2009Publication date: July 14, 2011Applicant: The University of British ColumbiaInventors: Bruce McManus, Zsuzsanna Hollander, Alice Mui, Robert Balshaw, Robert Mcmaster, Paul Keown, Gabriela Cohen Freue, Pooran Qasimi, Raymond Ng, David Lin, David Wishart, Axel Bergman
-
Publication number: 20100317038Abstract: A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.Type: ApplicationFiled: October 1, 2008Publication date: December 16, 2010Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus